C-NGJ7Itasca Therapeutics
precision oncology, RAS/MAPK pathway
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-NGJ7
C-NGJ7C-NGJ7precision oncology, RAS/MAPK pathway
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Itasca Therapeutics precision oncology, RAS/MAPK pathway
Erasca is a clinical-stage precision oncology company with a mission to erase cancer. The company is focused on shutting down the RAS/MAPK pathway, which it describes as one of cancer's most commonly mutated signaling cascades affecting approximately 5.5 million lives each year worldwide. Its pipeline is described as modality-agnostic and built to target the RAS/MAPK pathway at virtually every turn.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Itasca Therapeutics — Near-term readout · Bottom quartile. Derived deterministically from 10 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic